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Olfactory and rapid eye movement (REM) sleep deficits are commonly found in
untreated subjects with a recent diagnosis of Parkinson’s disease (PD). Additionally,
different studies report declines in olfactory performance during a short period of sleep
deprivation. Mechanisms underlying these clinical manifestations are poorly understood,
and impairment of dopamine (DA) neurotransmission in the olfactory bulb and the
nigrostriatal pathway may have important roles in olfaction and REM sleep disturbances.
Therefore, we hypothesized that modulation of the dopaminergic D2 receptors in the
olfactory bulb could provide a more comprehensive understanding of the olfactory
deficits in PD and REM sleep deprivation (REMSD). We decided to investigate the
olfactory, neurochemical, and histological alterations generated through the administration
of piribedil (a selective D2 agonist) or raclopride (a selective D2 antagonist) within the
glomerular layer of the olfactory bulb, in rats subjected to intranigral rotenone and REMSD.
Our findings provide evidence of the occurrence of a negative correlation (r = −0.52,
P = 0.04) between the number of periglomerular TH-ir neurons and the bulbar levels of
DA in the rotenone, but not sham, groups. A significant positive correlation (r = 0.34,
P = 0.03) was observed between nigrostriatal DA levels and olfactory discrimination
index (DI) for the sham groups, indicating that increased DA levels in the substantia nigra
pars compacta (SNpc) are associated with enhanced olfactory discrimination performance.
Also, increased levels in bulbar and striatal DA were induced by piribedil in the rotenone
control and rotenone REMSD groups, consistent with reductions in the DI. The present
evidence reinforce the idea that DA produced by periglomerular neurons, particularly the
bulbar dopaminergic D2 receptors, is an essential participant in olfactory discrimination
processes, as the SNpc, and the striatum.
Keywords: olfactory bulb, olfactory discrimination, dopamine, bulbar dopaminergic D2 receptors, REM sleep
deprivation, intranigral, Parkinson’s disease
INTRODUCTION
Olfactory deficits in odor detection (the threshold or the percep-
tion of odors at low concentrations), identification (the ability
to name an odor), and discrimination (the nonverbal distinction
of different smells) are commonly found in untreated subjects
with a recent diagnosis of Parkinson’s disease (PD; Tissingh et al.,
2001). These early dysfunctions are supported by neuropatho-
logic studies, with Lewy pathology present in the olfactory bulb,
olfactory tract and anterior olfactory nucleus in preclinical Braak
stages prior to significant nigral degeneration (Del Tredici et al.,
2002). Olfaction is impaired in approximately 90% of early-stage
PD cases and can precede the onset of motor symptoms by years
(Doty, 2012b).
It is reported a massive presence of dopaminergic inter-
neurons in the glomerular portion of the olfactory bulb and the
outer plexiform layer (Liberia et al., 2012). In PD the number
of tyrosine hydroxylase immunoreactive periglomerular neurons
(TH-ir) is increased with respect to age-matched controls, pos-
sibly reflecting a higher dopaminergic activity (Huisman et al.,
2004; Mundiñano et al., 2011). Such effect in the olfactory
bulb could lead to a suppression of olfactory information,
particularly due to the inhibitory effect of dopamine (DA;
Huisman et al., 2004), mediated by D2 receptors activity, on
the transmission between olfactory receptor cells and mitral
cells within the olfactory glomeruli (Sengoku et al., 2008), thus,
promoting the hyposmia (Doty and Risser, 1989; Koster et al.,
1999).
Rotenone exposure in rodents provides an interesting model
for studying mechanisms of toxin-induced dopaminergic neu-
ronal injury (Betarbet et al., 2000; Greenamyre et al., 2003;
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Segura Aguilar and Kostrzewa, 2004; Drolet et al., 2009; Dos
Santos et al., 2013). In this model, a massive inhibition of
mitochondrial complex I produces selective degeneration of the
dopaminergic nigrostriatal system and reproduces key patho-
logical features of clinical PD (Sherer et al., 2003; Alam and
Schmidt, 2004; Dos Santos et al., 2013). The pathophysiology
of olfactory loss in PD is unclear. Neuropathologic changes in
(1) the olfactolry bulb and the anterior olfactory nucleus in the
early disease; and (2) the olfactory cortex and limbic structures
in advances stages may both be involved (Benarroch, 2010).
Hyposmia has been related to nigrostriatal denervation in the
early stages of PD (Siderowf et al., 2005), whereas cholinergic
deficits in the limbic cortex may occur in later stages (Bohnen
et al., 2010). Thus, the use of intranigral rotenone, as a model
of PD, becomes attractive because it is strongly associated to the
presymptomatic state of PD (Moreira et al., 2012; Dos Santos
et al., 2013).
Another intriguing prodromal dysfunction found in PD con-
cerns the rapid eye movement (REM) sleep disorders (Lima et al.,
2012; Lima, 2013). Several findings demonstrated that normal
REM sleep can be suppressed in both normal and DA transporter
knockout mice without affecting motor functions by diminishing
dopaminergic tone (Dzirasa et al., 2006; Lima, 2013). A different
study reported that the selective D2 blockade may produce the
reduction or even suppression of REM sleep after a period of
REM sleep deprivation (REMSD; Lima et al., 2008; Lima, 2013).
Also, the lesion of the substantia nigra pars compacta (SNpc)
dopaminergic neurons provoked a major impairment in REM
sleep generation in rats (Lima et al., 2007) and rhesus mon-
keys (Barraud et al., 2009). Interestingly, different studies have
shown that REMSD, both in humans and rodents, is capable
to produce a significant impairment in an olfactory discrimi-
nation task (ODT), similar to PD (Greiner et al., 2001; Fantini
et al., 2006; Killgore and Mcbride, 2006; Killgore et al., 2008a,
2010.
These observations, together with recent evidence based on
the use of the intranigral rotenone model of PD (Moreira et al.,
2012; Dos Santos et al., 2013), have led to the hypothesis that
a modulation of the D2 receptors in the olfactory bulb could
provide a more comprehensive understanding of the olfactory
deficits mechanisms found in PD and after REMSD. In this
study, we decided to investigate the olfactory, neurochemical
and histological alterations generated by the administration of
piribedil or raclopride (selective D2 agonist and antagonist,
respectively), within the glomerular layer of the olfactory bulb,
in rats submitted to intranigral rotenone infusion. Concurrently,
we evaluated the effects of REMSD in the present experimental
paradigm.
MATERIAL AND METHODS
ETHICS STATEMENT
The studies were conducted in accordance with the guide-
lines of Brazilian Guide for Care and Use of Laboratory Ani-
mals (COBEA). In addition, the protocol complies with the
recommendations of Federal University of Paraná and was
approved by the Institutional Ethics Committee (approval ID
#658).
ANIMALS
Male Wistar rats from our breeding colony weighing 280–320 g
were used. The animals were randomly housed in groups of
five in polypropylene cages with wood shavings as bedding and
maintained in a temperature-controlled room (22 ± 2◦C) on a
12-h light-dark cycle (lights on at 7:00 AM). The animals had free
access to water and food throughout the experiment.
EXPERIMENTAL DESIGN
Before the stereotaxic surgeries the animals were distributed ran-
domly in two groups: Sham (n = 102) and Rotenone (n = 102).
After the surgery procedure, the animals were redistributed in
twelve groups (n = 17/group): sham control vehicle, sham control
piribedil, sham control raclopride, sham REMSD vehicle, sham
REMSD piribedil, sham REMSD raclopride, rotenone control
vehicle, rotenone control piribedil, rotenone control raclopride,
rotenone REMSD vehicle, rotenone REMSD piribedil, rotenone
REMSD raclopride. The concentrations of these drugs were
determined according to a concentration-effect curve previously
defined in an experiment based on locomotor and olfactory
parameters (see supplementary material, Figure 1). In addition,
regarding the olfactory discrimination evaluation, we included
another control group (n = 12) treated with Zicam (Matrixx Ini-
tiatives, Inc., Phoenix, AZ) intending to produce loss of olfaction
(Lim et al., 2009).
Stereotaxic surgeries were performed on day zero and on day
4 all animals were kept individually in their home cages for
48 h to collect sawdust for the ODT. On day 6, the REMSD
procedure started. Twenty four hours after, on day 7, the rats
received the intrabulbar administration of piribedil or raclo-
pride, subsequently (2 h after) they were tested (due to pharma-
cokinetics). Without delay, after the ODT, 10–12 animals/group
were decapitated, their brains removed and dissections of the
striatum, substantia nigra and olfactory bulb were subsequently
used for neurochemistry and molecular analyses. Others 3–5
animals/group had their brains perfused and fixed for subsequent
immunohistochemical analysis.
STEREOTAXIC SURGERY
Rats were sedated with intraperitoneal xylazine (10 mg/kg; Syn-
tec do Brasil Ltda, Brazil) and anesthetized with intraperitoneal
ketamine (90 mg/kg; Syntec do Brasil Ltda, Brazil). The fol-
lowing coordinates were used to the bilateral injury, bregma
as a reference: SNpc (AP) = −5,0 mm, (ML) = ± 2,1 mm
e (DV) = −8,0 mm (Paxinos and Watson, 2005). Needles
were guided to the region of interest for a bilateral infusion
of 1 µL of rotenone (12 µg/µL) or of dimethylsulfoxide—
DMSO (Sigma-Aldrich®, United States) using an electronic infu-
sion pump (Insight Instruments, Ribeirão Preto, Brazil) at a
rate of 0.33 µL/min for 3 min (Saravanan et al., 2005; Mor-
eira et al., 2012; Dos Santos et al., 2013). Complementarily, a
guide cannula was implanted in the olfactory bulb of each rat
allowing a subsequent 1 µL infusion of piribedil (3 µg/µL)
(Tocris Bioscience®, United Kingdom), raclopride (10 µg/µL)
(Sigma-Aldrich®, United States) or vehicle (DMSO) at a rate of
0.33 µL/min for 3 min, in their respective groups. Coordinates
with reference to bregma for implantation of guide cannula
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were: (AP) = +7.08 mm (ML) = 0.0 mm and (DV) = −3.6 mm
(Paxinos and Watson, 2005).
INTRANASAL ADMINISTRATION OF ZICAM (ZINC GLUCONATE + ZINC
ACETATE SOLUTION)
The administration of Zicam®Oral Mist (Matrixx Initiatives,
Scottsdale, AZ, USA) was performed as previously reported
by (Chioca et al., 2013): “the animals were sedated with an
intraperitoneal administration of 90 mg/kg ketamine and 3 mg/kg
xylazine, and approximately 30 µL of Zicam solution was slowly
delivered into the nasal cavity using a Hamilton syringe connected
to a blunted 30-gauge needle through a polyethylene tube. The
needle was inserted 15 mm past the right external nostril to help
irrigate the olfactory epithelium. The procedure was repeated
in the left nostril. During respiration, part of the solution was
expelled through the nostril and dried with absorbent paper to
allow the animal to continue breathing”.
REMSD PROCEDURE
REMSD was attained by means of the single platform method.
Rats were individually placed on a circular platform (6.5 cm in
diameter) in a cage (23× 23× 30 cm) filled with water up to 1 cm
below the platform level. At the onset of each REM sleep episode,
the animal experiences a loss of muscle tonus and falls into the
water, thus being awakened. When platforms of this size are
used, REM sleep is completely eliminated (Machado et al., 2004).
Throughout the study, the experimental room was maintained at
controlled conditions (22 ± 2◦C, 12 h light/dark cycle, lights on
7:00 a.m.). The control group was kept in the same room as the
REMSD rats during the study. Food and water were provided ad
libitum by placing chow pellets in a dispenser positioned inside
the cage and water bottles on a grid located on top of the tank.
OLFACTORY DISCRIMINATION TASK (ODT)
This test was previously described by Lamberty Soffie and subse-
quently modified by Prediger et al. (Soffié and Lamberty, 1988;
Prediger et al., 2005a,b). The version used has been modified
from (Prediger et al., 2005a). The apparatus consists of a box
(60 × 40 × 50 cm) equally divided into two compartments,
connected by a door that gives free access to the animal. Before
the test, the animals were allowed an adaptation period in the
apparatus of 5 min, in both compartments with fresh sawdust.
After that, clean sawdust is added on one side of the box (non-
familiar odor). Sawdust obtained from cages of animals isolated
for 48 h before testing was added to the other side of the box
(familiar odor). The ODT consists of placing the rat in the middle
of olfactory discrimination box and recording, up to 5 min,
the time of investigation of each compartment. The animal that
shows olfactory impairment tends to explore both compartments
equally, indicating absence of discrimination. As a parameter of
discrimination, a “discrimination index (DI)” was considered by
dividing the difference in exploration time between the two com-
partments (compartment non-familiar—compartment familiar)
by the total amount of exploration for both compartments (com-
partment non-familiar + compartment familiar). DI was then
multiplied by 100 to express it as a percentage (Dos Santos et al.,
2013).
NEUROCHEMICAL ANALYSIS OF STRIATAL, OLFACTORY BULB AND
SUBSTANTIA NIGRA NEUROTRANSMITTERS, METABOLITES AND
TURNOVERS
The brains were quickly removed from the skulls after decapi-
tation (about 30 s long) then were immediately placed on petri
dishes (covered with a filter paper) immersed on dry ice. The
striatum, olfactory bulb and the substantia nigra of the rats
were immediately dissected and placed on pre-weighed eppendorf
tubes that were weighed again with the structures. As previously
reported by (Moreira et al., 2012): “the samples were stored at
−80◦C until analysis. The endogenous concentrations of DA, 3,4-
dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA)
were assayed by reverse-phase high performance liquid chro-
matography (HPLC) with electrochemical detection (Barbiero
et al., 2011). The system consisted of a Synergi Fusion-RP C-18
reverse-phase column (150 × 4.6 mm i.d., 4 µm particle size)
fitted with a 4 × 3.0 mm pre-column (Security Guard Cartridges
Fusion-RP); an electrochemical detector (ESA Coulochem III
Electrochemical Detector) equipped with a guard cell (ESA 5020)
with the electrode set at 350 mV and a dual electrode analyt-
ical cell (ESA 5011A); a LC-20AT pump (Shimadzu) equipped
with a manual Rheodyne 7725 injector with a 20 µL loop.
The column was maintained inside in a temperature-controlled
oven (25◦C). The cell contained two chambers in series: each
chamber including a porous graphite coulometric electrode, a
double counter electrode and a double reference electrode. Oxi-
dizing potentials were set at 100 mV for the first electrode
and at 450 mV for the second electrode. The tissue samples
were homogenized with an ultrasonic cell disrupter (Sonics) in
0.1 M perchloric acid containing sodium metabisulfite 0.02%
and internal standard. After centrifugation at 10,000 × g for
30 min at 4◦C, 20 µL of the supernatant was injected into the
chromatograph”.
“The mobile phase, used at a flow rate of 1 mL/min, had the
following composition: 20 g citric acid monohydrated (Merck),
200 mg octane-1-sulfonic acid sodium salt (Merck), 40 mg
ethylenediaminetetraacetic acid (EDTA) (Sigma), 900 mL HPLC-
grade water. The pH of the buffer running solution was adjusted
to 4.0 then filtered through a 0.45 µm filter. Methanol (Merck)
was added to give a final composition of 10% methanol (v/v).
The neurotransmitters and metabolites concentrations were cal-
culated using standard curves that were generated by determining
in triplicate the ratios between three different known amounts
of the internal standard. The unit was expressed as ng/g of wet
weight”.
TH- IMMUNOHISTOCHEMISTRY WITHIN THE OLFACTORY BULB
Total number of TH-ir neurons was estimated in the glomerular
and plexiform layers of the olfactory bulb (Figure 5C). Animals
were deeply anesthetized with ketamine immediately after the
ODT, and were intracardially perfused with saline first, then with
4% of the fixative solution formaldehyde in 0.1 M phosphate
buffer (pH 7.4). Brains were removed from the skulls and were
immersed for 48 h in that fixative solution at 4◦C. Subsequently,
the brains were placed in 30% sucrose solution for 3 days and
were frozen at −80◦C before sectioning. Twelve 40 µm sections
per animal were taken from the olfactory bulb (+7.56 mm and
Frontiers in Cellular Neuroscience www.frontiersin.org December 2014 | Volume 8 | Article 383 | 3
Rodrigues et al. Bulbar D2-induced olfactory impairment
+7.08 mm an interval of 480µm). Tissue sections were incubated
with primary mouse anti-TH antibody, diluted in phosphate-
buffered saline containing 0.3% Triton X-100 (1:500; Chemicon,
CA, USA) overnight at 4◦C. Biotin-conjugated secondary anti-
body incubation (1:200 anti-mouse # Vector Laboratories, USA),
was performed for 2 h at room temperature. After several
washes in phosphate-buffered saline, antibody complex was
localized using the ABC system (Vectastain ABC Elite kit, Vector
Laboratories, USA) followed by 3,3′-diaminobenzidine reaction
with nickel enhancement. The sections were then mounted
onto gelatin-coated slides and coverslipped after dehydration in
ascending concentrations of ethanol-xylene solutions. Cell counts
were conducted making use of the software Image-Pro Express
6. Counts were done on 10–12 tissue sections (corresponding
to the 480 µm interval), and an average count per section (and
consequently for each animal) was obtained. For each group a
mean value was calculated and converted to a percentage relative
to the sham control vehicle, and compared with those of the other
groups. The mean number of TH-ir neurons in each hemisphere
was considered to be representative of the olfactory bulb neuronal
cells in each animal. The images were obtained using a motorized
Axio Imager Z2 microscope (Carl Zeiss, Jena, DE), equipped with
a automated scanning VSlide (Metasystems, Altlussheim, DE).
Statistical analysis
Differences between groups in the ODT were analyzed by
two-way analysis of variance (ANOVA) followed by the
Bonferroni post hoc test. Olfactory DI, neurochemical analy-
sis and TH-immunohistochemistry were analyzed by one-way
ANOVA followed by the Newman-Keuls multiple comparison
test. Pearson’s correlation coefficients (r) were calculated to estab-
lish relationships between neurochemical and behavioral param-
eters or molecular and neurochemical parameters. Values were
expressed as mean ± standard error of mean (SEM). The level
of significance was set at P ≤ 0.05.
RESULTS
OLFACTORY DISCRIMINATION TASK (ODT)
Regarding the time spent in each compartment in the ODT, we
found that the sham control vehicle group showed an increment
in time spent in the non-familiar odor compartment in rela-
tion to the familiar (P ≤ 0.001), as well as the sham control
piribedil (P≤ 0.05) and sham REMSD vehicle (P≤ 0.001) groups
(Figure 1A). In contrast, the sham control raclopride group
showed more time exploring the familiar odor compartment in
relation to the non-familiar (P ≤ 0.05) and that time spent in the
familiar compartment was significantly higher when compared to
the sham control piribedil group (P ≤ 0.05). In fact, the time
spent in the non-familiar compartment for the sham control
raclopride group was significantly lower in comparison to the
sham control vehicle (P ≤ 0.001) and sham control piribedil
(P ≤ 0.05) groups as indicated by the odor (F(12,292) = 8.46,
P < 0.0001), group (F(12,292) = 0.00, P = 1.00) and interaction
(F(12,292) = 8.46, P < 0.0001) factors (Figure 1A). In addition,
this analysis revealed that sham REMSD piribedil and sham
REMSD raclopride did not discriminated the compartments.
A similar result was obtained for all the rotenone groups, as
FIGURE 1 | (A) Time (s) spent in familiar and non-familiar compartments in
the olfactory discrimination task (ODT) 7 days after surgery. The bars
represent the mean ± standard error of the mean. n = 15 per group,
*P ≤ 0.05, ***P ≤ 0.001 comparing the time mean spent in familiar and
non-familiar compartments. Two-way ANOVA followed by the Bonferroni
test. (B) Olfactory discrimination index (DI) calculated by (NF-F/NF+F)*100,
NF is the time spent in the compartment with non-familiar odor and F is the
time spent in the compartment with familiar odor. The bars represent the
mean ± standard error of the mean, n = 15 per group, *P ≤ 0.05,
**P ≤ 0.01, ***P ≤ 0.001. One-way ANOVA followed by the
Newman-Keuls test.
well as for the Zicam group (positive control of olfactory loss)
(Figure 1A).
Figure 1B shows the DI for each group obtained during the
ODT. Accordingly, the sham control raclopride group exhibited a
significant impairment in the DI compared to the sham control
piribedil (P< 0.001) and sham control vehicle (P< 0.05) groups.
Likewise, the sham control raclopride group demonstrated a
significant reduction (P < 0.05) in this parameter in compari-
son to the rotenone control raclopride group (F(12,146) = 4.236,
P < 0.0001). In addition, the sham REMSD piribedil presented
a reduction (P < 0.05) in the DI compared to the sham REMSD
vehicle.
QUANTIFICATION OF BULBAR, NIGRAL AND STRIATAL DOPAMINE AND
METABOLITES
Figure 2 shows the alterations in the neurotransmission within
the olfactory bulb. Accordingly, DA levels (Figure 2A) were
reduced in the rotenone control vehicle group compared to the
sham control vehicle (P ≤ 0.01) and rotenone control piribedil
(P ≤ 0.01) groups (F(11,78)=3.678, P = 0.0003). Considering the
DOPAC levels (Figure 2B) it was observed that the rotenone
REMSD vehicle group presented an increase of this metabolite
Frontiers in Cellular Neuroscience www.frontiersin.org December 2014 | Volume 8 | Article 383 | 4
Rodrigues et al. Bulbar D2-induced olfactory impairment
FIGURE 2 | Neurochemical examination of the olfactory bulb content of DA and metabolites. (A) DA, (B) DOPAC, (C) HVA, (D) DA turnover. Values are
expressed as mean ± SEM. *P ≤ 0.05, **P ≤ 0.01. One-way ANOVA followed by the Newman Keuls test.
compared to the sham REMSD vehicle (P ≤ 0.05), rotenone
control vehicle (P ≤ 0.01) and rotenone REMSD raclopride
(P ≤ 0.01) groups (F(11,86) = 3.569, P = 0.0004). Figure 2C
shows the HVA levels in the olfactory bulb, that is increased in
the rotenone control vehicle group compared to the rotenone
REMSD vehicle group (P ≤ 0.05; F(11,80) = 2.146, P = 0.0259).
The calculation of the bulbar DA turnover (Figure 2D) indicated
no differences between groups (F(11,41) = 0.5327, P = 0.8696).
The neurochemical alterations in the substantia nigra are
shown in Figure 3. DA levels (Figure 3A) were found to be
reduced in the sham control raclopride group compared to the
sham control vehicle group (P ≤ 0.05). A rather similar result is
found for the sham REMSD raclopride group compared to sham
REMSD vehicle group (P ≤ 0.05), as well as for the rotenone
control raclopride group compared to rotenone control piribedil
group (P ≤ 0.05) (F(11,79) = 4.987, P < 0.0001). Regarding
the DOPAC levels (Figure 3B) the rotenone control raclopride
group presented a decrease in this metabolite in comparison to
the rotenone control vehicle group (P ≤ 0.01) (F(11,80)=2.978,
P = 0.0023). Figure 3C shows the HVA levels, that is increased
in the sham control raclopride group compared to the rotenone
control raclopride group (P ≤ 0.001). Furthermore, the sham
REMSD vehicle group exhibited a significant increase in HVA
compared to the rotenone REMSD vehicle group (P ≤ 0.05).
Besides, the sham REMSD raclopride group presented an incre-
ment in HVA levels compared to the rotenone REMSD raclopride
group (P ≤ 0.05). Likewise, the rotenone control vehicle group
showed an increase in HVA compared to the rotenone REMSD
vehicle (P ≤ 0.05) and rotenone control raclopride groups
(P ≤ 0.05) (F(11,87) = 6.768, P < 0,0001). The calculation of
the nigral DA turnover (Figure 3D) indicated that the rotenone
control vehicle group presented an increased turnover (P ≤ 0.05)
compared to the rotenone control piribedil and rotenone REMSD
vehicle groups (F(11,42) = 2.907, P = 0,0062).
In the striatum, the neurochemical alterations are shown in
Figure 4. DA levels (Figure 4A) were found to be reduced in the
sham control raclopride, sham REMSD vehicle and rotenone
control vehicle groups compared to the sham control vehicle
group (P ≤ 0.001). Similar results were found for the rotenone
control raclopride group compared to rotenone control piribedil
group (P ≤ 0.05) (F(11,75) = 5.654, P < 0.0001). Considering
the DOPAC levels (Figure 4B) no differences among the
groups (F(11,75)=1.872, P = 0.0567) were identified. Absence of
statistical significances were also found regarding the HVA levels
(F(11,76) = 1.572, P = 0.1243) (Figure 4C). The calculation of
the striatal DA turnover (Figure 4D) indicated that the rotenone
control vehicle group presented an increase in this parameter
compared to the sham control vehicle (P ≤ 0.05), rotenone
control piribedil (P ≤ 0.05), rotenone control raclopride
(P ≤ 0.05) and rotenone REMSD vehicle (P ≤ 0.01) groups
(F(11,37) = 2.593, P = 0,0149).
TH-IMMUNOHISTOCHEMISTRY
As can be seen in Figure 5A, the percentage of TH-ir neurons
within the glomerular layer of the olfactory bulb indicated that
a significant increase in TH-ir neurons was observed in the
sham control piribedil (P < 0.01) and sham control raclopride
(P < 0.01) groups in comparison to the sham control vehicle
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FIGURE 3 | Neurochemical examination of the substantia nigra content of DA, and metabolites. (A) DA, (B) DOPAC, (C) HVA, (D) DA turnover. Values are
expressed as mean ± SEM. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. One-way ANOVA followed by the Newman Keuls test.
group. Besides, the sham REMSD piribedil group exhibited a sig-
nificant increase of this parameter compared to the sham REMSD
vehicle (P < 0.001) and sham REMSD raclopride (P < 0.001)
groups. The sham REMSD raclopride group also presented a
decrease of TH-ir neurons compared to the sham control raclo-
pride group (P< 0.001). The intranigral rotenone administration
inflicted a rather opposite effect regarding the number of TH-
ir neurons, i.e., the rotenone control piribedil group showed
a decrease of this labeling compared to the rotenone control
vehicle (P < 0.001) and rotenone control raclopride (P < 0.05).
Moreover, the rotenone REMSD piribedil and rotenone REMSD
raclopride groups showed increased percentage in TH-ir neu-
rons in comparison to the rotenone REMSD vehicle group. In
addition, the rotenone REMSD piribedil group demonstrated an
increase in TH-ir neurons compared to the rotenone control
piribedil (P < 0.001). Remarkably the rotenone control piribedil
group exhibited a significant decrease in the percentage of TH-
ir neurons in comparison to the sham control piribedil group
(P < 0.001). In contrast, the rotenone control vehicle group
showed an increment in this labeling compared to the sham
control vehicle (P < 0.001). Moreover, a significant increase
(P < 0.001) was identified in the rotenone REMSD raclo-
pride group compared to the sham REMSD raclopride group
(F(11,28) = 17.80, P < 0.0001).
In relation to the plexiform layer of the olfactory bulb
(Figure 5B) a significant increase in TH-ir neurons was observed
in the rotenone control raclopride (P < 0.05) and rotenone
REMSD vehicle (P < 0.001) compared to their respective sham
groups. Additionally, an increment in the number of these neu-
rons was perceived in the rotenone REMSD vehicle group com-
pared to the rotenone control vehicle (P < 0.05) and rotenone
REMSD piribedil (P< 0.05) groups (F(11,30) = 7.504, P< 0.0001).
STATISTICAL CORRELATIONS BETWEEN BEHAVIORAL AND
NEUROCHEMICAL PARAMETERS OR MOLECULAR AND
NEUROCHEMICAL PARAMETERS
Pearson’s correlation coefficients (Table 1) revealed a moderate
negative correlation (r =−052; P = 0.04) between periglomerular
TH-ir neurons and bulbar DA levels for the rotenone groups. We
noted a weak, however, significant positive correlation (r = 0.34 ;
P = 0.03) between nigral DA levels and DI for the sham groups.
Also, it has been noted a significant positive correlation (r = 0.30;
P = 0.04) between striatal DA levels and DI for the rotenone
groups.
DISCUSSION
In the present study, we observed that both intranigral rotenone
and REMSD were able to produce olfactory dysfunction under
the modulation of D2 receptors within the glomerular layer of
the olfactory bulb. The extent of the olfactory deficit was mod-
erate, considering the effects of REMSD, and strongly associated
with D2 activation. However, rotenone evoked an overwhelming
impairment (possibly due to a ceiling effect) because additional
pharmacological manipulation did not continue to produce any
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FIGURE 4 | Neurochemical examination of the striatal content of DA and metabolites. (A) DA, (B) DOPAC, (C) HVA, (D) DA turnover. Values are expressed
as mean ± SEM. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. One-way ANOVA followed by the Newman Keuls test.
Table 1 | Pearson’s correlations between different behavioral,
neurochemical and histological parameters.
Correlations Groups
Sham Rotenone
Periglomerular TH-ir
neurons × bulbar DA r = 0.24; P = 0.25 r = −052; P = 0.04∗
Periglomerular TH-ir
neurons × nigral DA r = −0.21; P = 0.31 r = −032; P = 0.21
Periglomerular TH-ir
neurons × striatal DA r = −0.06; P = 0.76 r = −0.38; P = 0.14
Bulbar DA × DI r = −0.12; P = 0.40 r = −0.10; P = 0.49
Nigral DA × DI r = 0.34; P = 0.03∗ r = −0.21; P = 0.15
Striatal DA × DI r = 0.13; P = 0.37 r = 0.30; P = 0.04∗
∗Significant correlations are indicated.
difference. It is worth noting that in this study, we observed that
the olfactory effects generated by rotenone were quite similar to
the olfactory deficit inflicted by intranasal Zicam, which was used
as a positive control for olfactory impairment. This agent has
been reported to promote cytotoxicity in both mouse and human
nasal tissue, including a potential for the development of long-
lasting and possibly irreversible olfactory dysfunction (Lim et al.,
2009; Chioca et al., 2013). The neurotoxic effects of rotenone
have been typically associated with nigrostriatal dopaminergic
neurotransmission (Betarbet et al., 2000; Moreira et al., 2012;
Dos Santos et al., 2013); however, to the best of our knowledge,
this is the first study to compare variations in monoaminergic
neurotransmission within the olfactory bulb, striatum and SNpc
following rotenone exposure. In fact, rotenone alone appears to
reduce the level of DA in the olfactory bulb and striatum, whereas
REMSD produced a similar effect in the striatum. The blockade of
bulbar D2 receptors triggered a considerable suppression of DA,
which was also observed after REMSD, within the SNpc and stria-
tum. However, a notable increase in DA levels was detected in the
rotenone control piribedil group in the olfactory bulb, SNpc and
striatum. This increase was completely abolished in the rotenone
REMSD piribedil group. Moreover, the number of olfactory TH-
ir periglomerular neurons was increased in both the activated and
blocked D2 receptors of the sham control groups. Conversely,
only D2 activation was able to increase this labeling in the
presence of REMSD. Additionally, rotenone plus REMSD led to a
drastic reduction in the number of rescued TH-ir neurons, most
likely by the D2 agonist piribedil. These data are in accordance
with previous reports that also described the involvement of the
dopaminergic system in olfaction (Mundiñano et al., 2011; Hutter
and Chapman, 2013; Borghammer et al., 2014). We suppose that
the increased olfactory TH-ir neurons that we observed following
rotenone treatment might be the result of phenotypic and perhaps
epigenetic changes in pre-existing olfactory GABAergic neurons.
Various studies have observed a decline in olfactory perfor-
mance during a short period of sleep deprivation (Killgore and
Mcbride, 2006; Killgore et al., 2008b, 2010). Furthermore, the
relationship between dopaminergic neurotransmission and REM
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FIGURE 5 | (A) Percentage of TH-ir expressing neurons in the glomerular
layer of the olfactory bulb in relation to sham control vehicle group. The bars
represent the mean ± standard error of the mean, n = 5 per group,
*P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. One-way ANOVA followed by the
Newman-Keuls test. (B) Percentage of TH-ir expressing neurons in the
external plexiform layer of the olfactory bulb in relation to sham control
vehicle group. The bars represent the mean ± standard error of the mean,
n = 5 per group, *P ≤ 0.05, ***P ≤ 0.001. One-way ANOVA followed by the
Newman-Keuls test. (C) Schematic diagram representing the coordinates
(mm) and sections used in immunohistochemistry for TH in the glomerular
layer (triangle) and external plexiform layer (circle) of the olfactory bulb
(adapted from Paxinos and Watson, 2005).
sleep is a recent theme in the literature, and growing evidence
suggests a significant impact of PD on REM sleep disturbances
(Lima, 2013). In addition, electrophysiological data indicate that
the loss of half of the SNpc TH-ir neurons in rats provoked a
major impairment in sleep-wake patterns, predominantly affect-
ing REM sleep (Lima et al., 2007). In addition, REM sleep could
be recovered in dopaminergic transporter knockout (DAT-KO)
mice via selective activation of the D2(but not the D1) receptor,
suggesting a particular role for this receptor in the regulation
of REM sleep (Dzirasa et al., 2006). The involvement of DA
has previously been reported following sleep deprivation pro-
tocols, indicating direct involvement in the generation of burly
dopaminergic D2 supersensitivity (Tufik et al., 1978; Tufik, 1981;
Nunes Júnior et al., 1994). In a similar vein, our findings provide
evidence of a negative correlation (r = −0.52, P = 0.04) between
the number of periglomerular TH-ir neurons and the bulbar
levels of DA in the rotenone(but not the sham) group. That is,
a decrease in the number of TH-ir neurons in the olfactory bulb
tends to promote an increase in DA that is expressed exclusively
in periglomerular cells (Hálasz et al., 1977). This effect is also
associated with the olfactory deficit that is promoted by rotenone
and counteracted by piribedil but not raclopride.
During a neurodegenerative disorder, periglomerular
dopaminergic interneurons release DA and gamma aminobutyric
acid (GABA; Mundiñano et al., 2011), which inhibit
glutamatergic neurotransmission from receptor neurons to
the hyperactivated mitral cells (Hsia et al., 1999; McKeith
et al., 2005). Mundiñano et al. (2011) suggested that changes
in centrifugal afferents to the olfactory bulb lead to changes
in mitral cell activity, which are followed by compensation via
an increase in the number of periglomerular dopaminergic
cells to adjust for the mitral cell activity imbalance. This
compensatory increase in dopaminergic inhibitory drive might
underlie hyposmia in PD patients (Mundiñano et al., 2011). In
accordance with these findings, a significant positive correlation
(r = 0.34, P = 0.03) was observed between nigral DA and the
DI in the sham groups, indicating that increased DA levels in
the SNpc are associated with enhanced olfactory discrimination
performance. Nevertheless, our study failed to detect possible
significant negative correlations between the groups (r = −0.12;
P = 0.40 for the sham groups and r = −0.10; P = 0.49 for
the rotenone groups) with respect to the levels of DA in the
olfactory bulb. A similar correlation (r = 0.30, P = 0.04) was
identified between striatal DA and the DI in the rotenone
groups.
D2 receptors are the most numerous subtype of DA recep-
tors in the olfactory bulb (Coronas et al., 1997). It has been
reported that one purposeful effect of D2 receptor activation
in the olfactory bulb is a significant depression in synaptic
transmission between olfactory receptor neurons and mitral cells
(Hsia et al., 1999). Interestingly, we administered concentra-
tions of piribedil and raclopride, which had been obtained from
a preliminary study (supplementary material Figure 1), that
increased and decreased, respectively, olfactory discrimination
performance without causing locomotor bias (supplementary
material Figure 2). However, this result contradicts the previous
statement that a potential limitation of our data is due to the
additional effect of piribedil on D3 receptors (Cagnotto et al.,
1996). According to (Gutièrrez-Mecinas et al., 2005), “there is
no other anatomical evidence demonstrating that D2 receptors
are presynaptically located in glutamatergic synapses from the
olfactory nerve onto mitral/tufted cells and periglomerular cells”.
Furthermore, the occurrence of D2 receptors in the other com-
ponents that form the glomerular circuitry (i.e., intraglomerular
dendrites of mitral/tufted cells and periglomerular cells) has not
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yet been analyzed, as previously reported (Gutièrrez-Mecinas
et al., 2005).
It has been verified that DA and a D2 agonist (bromocriptine)
are able to modulate GABAA receptors, promoting GABAergic
responses in cultured mitral and tufted cells within the rat olfac-
tory bulb (Brünig et al., 1999). An analogous effect of DA and
D2 receptors cannot be discarded in the intraglomerular den-
drites of in vivo cells, taking into account that GABAA receptors
are present in the mitral/tufted cells of the rat olfactory bulb
(Giustetto et al., 1998; Panzanelli et al., 2004; Gutièrrez-Mecinas
et al., 2005). If the activation of D2 receptors regulates GABAA
receptors and thereby facilitates GABAergic neurotransmission
from TH-ir periglomerular neurons, one would expect to observe
an increase in the inhibition of mitral/tufted cells (Tillerson et al.,
2006). Alternatively, the blockade of pre-synaptic D2 receptors by
raclopride in olfactory receptor neurons could trigger an increase
in glutamate release, consequently activating the dopaminergic
juxtaglomerular neurons and increasing the levels of DA, as well as
GABA, from these cells (O’Connor and Jacob, 2008; Doty, 2012a).
This mechanism may induce an inhibitory effect triggered by the
post-synaptic D2 and GABAA receptors that promotes olfactory
impairment. It is worth noting that we observed increased levels
of bulbar, nigral and striatal DA induced by piribedil in the
rotenone control and rotenone REMSD groups that were consis-
tent with the observed reduction in the DI (which was close to 3%
and similar to the effect of Zicam 4.5%). It is therefore conceivable
that the activation of D2 by piribedil, which is associated with
the well-known dopaminergic D2 supersensitivity induced by
rotenone and also by REMSD, could enhance this inhibitory
effect generated by D2 receptors and thereby promote a massive
impairment in olfactory function.
The present findings provide new information regarding the
roles of DA and D2 receptors within the olfactory bulb, SNpc and
striatum during olfactory discrimination. Rotenone promoted a
remarkable level of olfactory impairment that was modulated by
REMSD via D2 receptors. Indeed, D2 receptor activation can
enhance or impair the ability to discriminate odors, presumably
by altering the perceived intensity of a given odorant through
changes in the effective sensitivity of bulbar neurons to olfactory
sensory neuron input (Wei et al., 2006; Escanilla et al., 2009).
DA concentrations have also been found to increase during odor
learning process (Coopersmith et al., 1991), suggesting that DA
modulation may play important roles in synaptic plasticity within
the bulb while also influencing other areas, such as the SNpc
and striatum. Therefore, the present evidence reinforces that the
DA produced by periglomerular TH-ir neurons and the bulbar
dopaminergic D2 receptors are essential participants in olfactory
discrimination processes, as well as in the SNpc and striatum.
Consequently, these changes may have a direct impact on the
prodromal abnormalities found in patients with PD.
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